A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

NCT05479058 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
22
Enrollment
INDUSTRY
Sponsor class

Stopped the planned number of participants needed to ensure adequate precision in the estimations and to draw meaningful conclusions was unlikely to be met, questioning the scientific value and ethical grounds for study continuation

Conditions

Interventions

Sponsor

Lakefront Biotherapeutics NV